09:28 AM EDT, 06/18/2024 (MT Newswires) -- Alvotech ( ALVO ) and Advanz Pharma said Tuesday that they have signed a partnership agreement to supply and commercialize Alvotech's ( ALVO ) proposed biosimilar to Eylea in Europe.

Financial terms of the partnership weren't disclosed.

Alvotech ( ALVO ) is currently developing AVT06, a proposed low-dose biosimilar to Eylea, and AVT29, a high-dose biosimilar candidate to Eylea, the companies said.

The partnership stipulates that Alvotech ( ALVO ) will develop and commercially supply AVT06 and AVT29, while Advanz Pharma will register and commercialize them, the companies said.

Eylea treats eye disorders, including diseases leading to vision loss or blindness, the companies said.